# BrUOG 397: NEO Rad (LOW): Neoadjuvant Low Dose Stereotactic Body Radiotherapy, Ipilimumab and Nivolumab

> **NCT04933903** · PHASE2 · RECRUITING · sponsor: **Brown University** · enrollment: 25 (estimated)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** Ipilimumab
- **DRUG:** Nivolumab
- **RADIATION:** SBRT

## Key facts

- **NCT ID:** NCT04933903
- **Lead sponsor:** Brown University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-10-05
- **Primary completion:** 2026-06
- **Final completion:** 2026-09
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2026-03-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04933903

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04933903, "BrUOG 397: NEO Rad (LOW): Neoadjuvant Low Dose Stereotactic Body Radiotherapy, Ipilimumab and Nivolumab". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04933903. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*